A Phase 2 interventional study of SHR-1210 and Apatinib in Carcinoma, Non-Small-Cell Lung, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-03.
Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung — 6 open to participants now, 7 under way, 1 of them phase 3. camrelizumab · Carcinoma, Non-Small-Cell Lung.
Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 17 in phase 2, and was the 1st registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →6 of the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Henan Cancer Hospital · Sites in China
Ages 18+
CrystalGenomics, Inc. · Sites in Korea, Republic of
Ages 19–80
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–80
Shandong Cancer Hospital and Institute · Sites in China
Ages 18–75
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 18 · Phase 3 5
First in 2017; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 210 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 58 across the 27 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 27 have an industry lead sponsor. The 10 most frequent:
Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd.: 18 open now, 22 under way, 10 of them phase 3. Of 7 finished, 1 (14%) have results posted.
Among the 38 studies in Carcinoma, Non-Small-Cell Lung by Jiangsu HengRui Medicine Co., Ltd., this one is the 21st largest by enrollment, is one of 3 that started in 2017, is one of 14 in phase 2, and was the 5th registered.
Jiangsu HengRui Medicine Co., Ltd.’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2010.
None of the studies under way reaches primary completion within a year.
Among the 27 studies testing camrelizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Jiangsu HengRui Medicine Co., Ltd.’s 38 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label, Phase II study of intravenous (IV) SHR-1210 at 200mg, q2w in combination with Apatinib at two dose levels in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
The study is composed of two parts. Part 1 of the study will determine the safety, tolerability and pharmacokinetics of SHR-1210 in combination with Apatinib.
Part 2 includes a randomized comparison of Apatinib 250mg/d or 500mg/d plus SHR-1210.
Subject's tumors will be screened at baseline for EGFR mutations, EML4-ALK translocation, and PD-L1 expression.But positive tumor PD-L1 expression will not be required for enrollment.
SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI). A disease-control rate of 61.1% and a mPFS of 4.7 months were showed in Apatinib phase II study in patients with NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHR-1210 200mg, IV, Q2W and Apatinib 250mg, PO, QD
Biological: SHR-1210 · Drug: Apatinib
SHR-1210 200mg, IV, Q2W and Apatinib 500mg, PO, QD
Biological: SHR-1210 · Drug: Apatinib
SHR-1210 200mg, IV, Q2W and Apatinib 375mg, PO, QD
Biological: SHR-1210 · Drug: Apatinib
Incidence and Grade of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of participants with Adverse Events and Serious Adverse Events
Time frame: from signing the informed consent form to safety follow-up, 61 months
Objective Response Rate (ORR):
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: from first administration to progressive disease or initiation of new anti-cancer therapy, 61 months
| Milestone | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group |
|---|---|---|---|---|
| Started | 130 | 43 | 25 | 12 |
| Treated | 130 | 43 | 25 | 12 |
| Completed | 75 | 25 | 13 | 1 |
| Not completed | 55 | 18 | 12 | 11 |
Number of participants with Adverse Events and Serious Adverse Events
| participants | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group |
|---|---|---|---|---|
| Number of Subjects with AEs | 130 | 43 | 25 | 12 |
| Number of Subjects with SAEs | 82 | 21 | 9 | 7 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Percentage of participants | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group |
|---|---|---|---|---|
| Objective Response Rate (ORR): | 28.5 (20.9 to 37.0) | 18.6 (8.4 to 33.4) | 40.0 (21.1 to 61.3) | 16.7 (2.1 to 48.4) |
Collected over from signing the informed consent form to safety follow-up, 61 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Apatinib 250 mg Group | 48/198 (24.2%) | 112/198 (56.6%) | 197/198 (99.5%) |
| Apatinib 375 mg Group | 3/12 (25%) | 7/12 (58.3%) | 12/12 (100%) |
| Event | Apatinib 250 mg Group | Apatinib 375 mg Group |
|---|---|---|
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 19/198 | 2/12 |
| Immune-mediated hepatitisHepatobiliary disorders | 2/198 | 2/12 |
| Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders | 8/198 | 1/12 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/198 | 1/12 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/198 | 1/12 |
| Venous thrombosis limbVascular disorders | 0/198 | 1/12 |
| Hepatic function abnormalHepatobiliary disorders | 11/198 | 0/12 |
| DeathGeneral disorders | 10/198 | 0/12 |
| PneumoniaInfections and infestations | 8/198 | 0/12 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/198 | 0/12 |
| Event | Apatinib 250 mg Group | Apatinib 375 mg Group |
|---|---|---|
| RashSkin and subcutaneous tissue disorders | 66/198 | 11/12 |
| HypertensionVascular disorders | 126/198 | 10/12 |
| Decreased appetiteMetabolism and nutrition disorders | 66/198 | 9/12 |
| ProteinuriaRenal and urinary disorders | 125/198 | 9/12 |
| Aspartate aminotransferase increasedInvestigations | 106/198 | 8/12 |
| AstheniaGeneral disorders | 70/198 | 7/12 |
| Alanine aminotransferase increasedInvestigations | 89/198 | 7/12 |
| PyrexiaGeneral disorders | 56/198 | 6/12 |
| Weight decreasedInvestigations | 41/198 | 6/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 63/198 | 6/12 |
| Age, Continuous(years) | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group | Total |
|---|---|---|---|---|---|
| Median | 59.0 (35 to 70) | 55.0 (33 to 69) | 61.0 (47 to 69) | 55.5 (43 to 68) | 59 (33 to 70) |
| Sex: Female, Male(Participants) | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group | Total |
|---|---|---|---|---|---|
| Female | 28 | 18 | 6 | 2 | 54 |
| Male | 102 | 25 | 19 | 10 | 156 |
| Race (NIH/OMB)(Participants) | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 130 | 43 | 25 | 12 | 210 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Driver Gene Negative Population | Driver Gene Positive Population | Cohort 4 | Apatinib 375 mg Group | Total |
|---|---|---|---|---|---|
| China | 130 | 43 | 25 | 12 | 210 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Mar 2017 to primary completion in Apr 2022, 61 months.
Results were first posted in Mar 2026, 3 years 10 months after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 61 months is above that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Camrelizumab
Carcinoma, Non-Small-Cell Lung →
Jiangsu HengRui Medicine Co., Ltd. →